# OnCo record paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019" ;
  schema:name "Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours"@en ;
  schema:alternateName "Chung 2019"@en, "FoundationOne prostate 3476"@en, "real-world prostate genomic profiling"@en ;
  schema:description "The largest routine-practice picture of what is broken in prostate tumours. Across 3,476 samples sent for commercial sequencing, TP53 was altered in 44 percent and PTEN in 32 percent, and just over half carried something a drug is being developed against."@en ;
  schema:url <https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/po.18.00283>, <https://pubmed.ncbi.nlm.nih.gov/31218271/>, <https://europepmc.org/article/MED/31218271> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1200/po.18.00283> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Chung JH, Dewal N, Sokol E, et al." ;
  onco:related <https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/>, <https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/pten/>, <https://onco.cc/targets/erg/>, <https://onco.cc/targets/tmprss2/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/cdk12/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/foundation-medicine/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/genome-wide-loss-of-heterozygosity/>, <https://onco.cc/terms/chromoplexy/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-real-world-evidence/> ;
  onco:journals <https://onco.cc/journals/jco-precision-oncology/> .